RxDoctor Payments Data

Hua Zhong, MD

Internal Medicine · Alpharetta, GANPI 1821045279

Payments from drug & device makers

$4,831in general payments, 2019–2025

Across 125 payments — averaging $38.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$611
  • Novo Nordisk$530
  • AstraZeneca$397
  • Lilly USA, LLC$362
  • Sanofi-aventis U.S. LLC$267
  • Eisai Inc.$218
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$4,831100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,831 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$47,728
Medicare patients
137
Services billed
524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate34$36,554
JardianceEmpagliflozin29$23,050
OzempicSemaglutide21$19,577
Atorvastatin Calcium487$2,175
Losartan Potassium309$1,874
Nifedipine ErNifedipine47$1,282
Amlodipine Besylate339$1,265
Rosuvastatin Calcium83$1,254
Valsartan27$1,216
Metformin Hcl ErMetformin Hcl232$1,097
Levothyroxine Sodium190$990
ValacyclovirValacyclovir Hcl11$958
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide12$694
Alendronate Sodium126$611
Metoprolol Succinate48$576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$104$36,55434 claims
Boehringer IngelheimJardiance$15$23,05029 claims
Novo NordiskOzempic$530$19,57721 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$102$990190 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Alpharetta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →